Cargando…

Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro‐arrhythmia Assay initiative studies

BACKGROUND AND PURPOSE: We evaluated the concordance of results from two sets of nonclinical cardiovascular safety studies on pitolisant. EXPERIMENTAL APPROACH: Nonclinical studies envisaged both in the International Conference on Harmonization (ICH) S7B guideline and Comprehensive in vitro Pro‐arrh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ligneau, Xavier, Shah, Rashmi R, Berrebi‐Bertrand, Isabelle, Mirams, Gary R, Robert, Philippe, Landais, Laurent, Maison‐Blanche, Pierre, Faivre, Jean‐François, Lecomte, Jeanne‐Marie, Schwartz, Jean‐Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2017
Materias:	Research Papers
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715595/ https://www.ncbi.nlm.nih.gov/pubmed/28941245 http://dx.doi.org/10.1111/bph.14047

Ejemplares similares

Pitolisant, a wake‐promoting agent devoid of psychostimulant properties: Preclinical comparison with amphetamine, modafinil, and solriamfetol
por: Krief, Stéphane, et al.
Publicado: (2021)

Long-term use of pitolisant to treat patients with narcolepsy: Harmony III Study
por: Dauvilliers, Yves, et al.
Publicado: (2019)

Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial
por: Dauvilliers, Yves, et al.
Publicado: (2020)

Update on the treatment of narcolepsy: clinical efficacy of pitolisant
por: Calik, Michael W
Publicado: (2017)

Efficacy of Pitolisant on the Treatment of Narcolepsy: A Systematic Review
por: Fabara, Stephanie P, et al.
Publicado: (2021)

Clinical Impact of Pitolisant on Excessive Daytime Sleepiness and Cataplexy in Adults With Narcolepsy: An Analysis of Randomized Placebo-Controlled Trials
por: Meskill, Gerard J., et al.
Publicado: (2021)

Profile of pitolisant in the management of narcolepsy: design, development, and place in therapy
por: Romigi, Andrea, et al.
Publicado: (2018)

Treat the Symptom, Not the Cause? Pitolisant for Sleepiness in Obstructive Sleep Apnea
por: Trotti, Lynn Marie
Publicado: (2020)

Time to Onset of Response to Pitolisant for the Treatment of Excessive Daytime Sleepiness and Cataplexy in Patients With Narcolepsy: An Analysis of Randomized, Placebo-Controlled Trials
por: Watson, Nathaniel F., et al.
Publicado: (2021)

Orgasmolepsy in Narcolepsy Type 1 Responsive to Pitolisant: A Case Report
por: Pellitteri, Gaia, et al.
Publicado: (2020)

Evaluation of the abuse potential of pitolisant, a selective H(3)-receptor antagonist/inverse agonist, for the treatment of adult patients with narcolepsy with or without cataplexy
por: Setnik, Beatrice, et al.
Publicado: (2019)

Comparison of modafinil and pitolisant in narcolepsy: a non-inferiority meta-analytical approach
por: Lehert, Philippe, et al.
Publicado: (2020)

Pitolisant to Treat Excessive Daytime Sleepiness and Cataplexy in Adults with Narcolepsy: Rationale and Clinical Utility
por: Guevarra, Jay T, et al.
Publicado: (2020)

Pitolisant and Other Histamine-3 Receptor Antagonists—An Update on Therapeutic Potentials and Clinical Prospects
por: Harwell, Victoria, et al.
Publicado: (2020)

The histamine H(3) receptor inverse agonist pitolisant reduces body weight in obese mice
por: Kotańska, Magdalena, et al.
Publicado: (2018)

Clinical characteristics of a large cohort of patients with narcolepsy candidate for pitolisant: a cross-sectional study from the Italian PASS Wakix® Cohort
por: Mutti, Carlotta, et al.
Publicado: (2022)

H(3) histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice
por: Dudek, Magdalena, et al.
Publicado: (2016)

Explaining Differences Between Sibling Relationships in Schizophrenia and Nonclinical Sibling Relationships
por: Plessis, Léa, et al.
Publicado: (2020)

Nonclinical statistics for pharmaceutical and biotechnology industries
por: Zhang, Lanju
Publicado: (2016)

Strategies for the Nonclinical Safety Assessment of Vaccines
por: Wolf, Jayanthi J., et al.
Publicado: (2012)

The impact of pitolisant, an H(3) receptor antagonist/inverse agonist, on perirhinal cortex activity in individual neuron and neuronal population levels
por: Hirano, Kyosuke, et al.
Publicado: (2022)

Paracingulate Sulcus Morphology and Hallucinations in Clinical and Nonclinical Groups
por: Garrison, Jane R, et al.
Publicado: (2019)

Screening tools for brief interventions in nonclinical settings
por: Jones, Craig, et al.
Publicado: (2013)

Nonclinical Development of BCG Replacement Vaccine Candidates
por: Velmurugan, Kamalakannan, et al.
Publicado: (2013)

Psychosis proneness, loneliness, and hallucinations in nonclinical individuals
por: Lincoln, Sarah Hope, et al.
Publicado: (2021)

The Majority of Complaints About Orthopedic Sports Surgeons on Yelp Are Nonclinical
por: Pollock, Jordan R., et al.
Publicado: (2021)

Erratum: Pitolisant for Daytime Sleepiness in Patients with Obstructive Sleep Apnea Who Refuse Continuous Positive Airway Pressure Treatment. A Randomized Trial
Publicado: (2020)

Estudio WAKE de vida real en pacientes con narcolepsia con cataplejía tratados con pitolisant no respondedores a tratamientos previos
por: del Río-Villegas, Rafael, et al.
Publicado: (2022)

Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects
por: Patel, Dipak R., et al.
Publicado: (2021)

Deciphering second harmonic generation signals
por: Foucaud, Yann, et al.
Publicado: (2021)

Translation of Anticancer Efficacy From Nonclinical Models to the Clinic
por: Stroh, M, et al.
Publicado: (2014)

Book Review: Toxicologic Pathology, Nonclinical Safety Assessment
por: Yoshizawa, Katsuhiko
Publicado: (2014)

A Framework for Assessing the Value of Investments in Nonclinical Prevention
por: Miller, George, et al.
Publicado: (2015)

Voice-selective prediction alterations in nonclinical voice hearers
por: Pinheiro, Ana P., et al.
Publicado: (2018)

Nonclinical and clinical pharmacology evidence for cardiovascular safety of saxagliptin
por: Pollack, Pia S., et al.
Publicado: (2017)

Modeling the Influence of Nonclinic Visits on the Transmission of Respiratory Diseases
por: Bao, Yunting, et al.
Publicado: (2020)

Cryolipolysis: Clinical Best Practices and Other Nonclinical Considerations
por: Few, Julius, et al.
Publicado: (2020)

Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
por: Fisher, J. Edward
Publicado: (2021)

Development of COVID-19 therapies: Nonclinical testing considerations
por: Baldrick, Paul
Publicado: (2022)

Essential nonclinical competencies for cardiovascular specialists imperatives for training
por: Valentine, C. Michael, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rmfsons1m3qp7hsc58r5uh1sm4